DESTINY-Breast 05 is a phase 3, multicenter, randomized, open-label, active-controlled trial comparing T-DXd to T-DM1 in patients with high-risk HER2-positive primary breast cancer who have residual invasive disease in the breast or axillary lymph nodes following neoadjuvant therapy. Here, ERBB2 is linked to breast cancer.